https://www.live-feeds.com/feed/moderna-shares-surge-as-melanoma-vaccine-with-merck-succeeds-in-large-trialContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/moderna-shares-surge-as-melanoma-vaccine-with-merck-succeeds-in-large-trialhttps://www.live-feeds.com/feed/moderna-shares-surge-as-melanoma-vaccine-with-merck-succeeds-in-large-trial#u46855Sun, 23 Aug 2026 11:21:06 +0000An experimental personalized mRNA vaccine developed by Moderna and Merck successfully completed Phase 3 clinical trials. This milestone is the final requirement before the vaccine can seek FDA approval. The treatment aims to prevent melanoma recurrence and has sparked optimism regarding a new generation of cancer therapies. Following these results, Moderna shares experienced a significant surge.Why it mattersThe vaccine utilizes mRNA technology to create personalized treatments tailored to individual patients. Success in Phase 3 trials indicates the drug is ready for regulatory review to deter https://www.live-feeds.com/feed/moderna-shares-surge-as-melanoma-vaccine-with-merck-succeeds-in-large-trialhttps://www.live-feeds.com/feed/moderna-shares-surge-as-melanoma-vaccine-with-merck-succeeds-in-large-trial#u45483Thu, 20 Aug 2026 07:30:53 +0000Moderna's melanoma vaccine, developed with Merck, showed promise in a large trial, leading to a significant surge in Moderna's shares. The vaccine, which uses mRNA technology, met its primary goal in preventing the recurrence of melanoma. This development has generated optimism about the potential of the vaccine to treat cancer.Why it mattersThe collaboration between Moderna and Merck aims to leverage mRNA technology to develop innovative cancer treatments. Melanoma is a serious form of skin cancer, and the current treatment options have limitations. The success of this vaccine could